Delisting risk
SciSparc (SPRC)
Develops cannabinoid drug candidates and sells Wellution hemp and personal-care products through Amazon.
$5.76
Pre-market−0.08 (−1.37%)
At close$5.84(+3.00%)
In millions of USD, except per-share figures
| In millions | Q2 FY20Jun 2020 | Q4 FY20Dec 2020 | Q2 FY21Jun 2021 | Q4 FY21Dec 2021 | Q2 FY22Jun 2022 | Q4 FY22Dec 2022 | Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 1 | 1 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1 | 3 | 3 | 5 | 5 | 4 | −4 | −3 | 11 | 9 | 0 | |
| Research & development | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 1 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | −1 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| General & administrative | 1 | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 0 | 5 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −8 | −7 | 7 | 0 | 0 |
| Operating income | −1 | −1 | −3 | −3 | −5 | −3 | −3 | 4 | 4 | −11 | −9 | 0 |
| −1 | −6 | 0 | −9 | −1 | −10 | 0 | −7 | −7 | 7 | 0 | −4 | |
| Interest income | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 2 |
| Interest expense | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 7 |
| Other non-operating income | 0 | 6 | 0 | 9 | 0 | 17 | 0 | 7 | 7 | −7 | 0 | 0 |
| Income before tax | −3 | −1 | −3 | −3 | −6 | 3 | −3 | −3 | −4 | −4 | −9 | −3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −3 | −1 | −3 | −3 | −6 | 3 | −3 | −3 | −4 | −4 | −9 | −3 |
| Net income | −3 | −1 | −3 | −3 | −6 | 3 | −3 | −2 | −3 | −3 | −9 | −3 |
| EPS, basic | $0.00 | $0.00 | −$355.68 | −$311.94 | −$421.20 | $124.47 | −$97.65 | −$36.63 | −$15.30 | −$12.63 | −$161.28 | −$70.21 |
| EPS, diluted | $0.00 | $0.00 | −$1,778.40 | −$1,564.65 | −$2,106.00 | $619.20 | −$488.25 | −$245.70 | −$76.50 | −$12.63 | −$161.28 | −$70.21 |
| Weighted average shares, basic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Weighted average shares, diluted | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | −1 | −1 | −3 | 6 | −5 | −3 | −3 | −3 | −3 | −4 | −9 | 0 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −1 | −3 | −3 | −5 | −3 | −3 | −3 | −4 | −4 | −9 | 0 |